

**Surgical Innovations Group plc**  
("Surgical Innovations", the "Company", or the "Group")

**Trading update**

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery, provides the following update on trading ahead of its year ended 31 December 2025.

Sales in the final quarter have been softer than anticipated due to a number external factors including:

- The global flu epidemic is impacting the Group across its key markets in Europe, APAC and ROW and has led to a reduction in elective surgical procedures.
- This has been compounded by continued industrial action in the NHS taking place in September and further strikes scheduled for next week, contributing to additional delays in elective procedures and increased seasonal pressure on NHS capacity.
- Sales in December have also been adversely affected by a one-off quality issue relating to key components supplied by an OEM partner, which constrained our manufacturing of their product. The issues have been promptly addressed and supply is resuming, with normal deliveries expected in early 2026.

As a result of these unanticipated market factors, the Company expects revenues for the year to now be c. £11.5m with a commensurate impact on profits. In addition, as part of its review of year-end inventory holdings, the Board has taken the prudent decision to increase its provision held against slow moving raw material stock.

Net debt as of 17 December 2025 was £0.4m and the Company continues to closely monitor its working capital position.

The Board remains confident of the growing focus on environmental sustainability driving organisations to adopt greener practices, with Surgical Innovations well positioned to capitalise on offering a sustainable solution with the Company's reposable™ technology aligning with this shift.

**David Marsh, CEO of Surgical Innovations, said:** *"Whilst we are naturally disappointed with the external market forces having a direct impact on the Group's performance, we remain confident in our reposable™ technology and the overall prospects of the Group going forward. We look forward to updating shareholders at our full year results."*

**For further information please contact:**

**Surgical Innovations Group plc**  
David Marsh, CEO  
Brent Greetham, CFO

[www.sigroupplc.com](http://www.sigroupplc.com)  
Tel: 0113 230 7597

**Singer Capital Markets (Nominated Adviser & Broker)**  
Alex Bond / Graham Hertrich

Tel: 020 7496 3000

**Walbrook PR (Financial PR & Investor Relations)**  
Paul McManus / Lianne Applegarth

Tel: 020 7933 8780 or [si@walbrookpr.com](mailto:si@walbrookpr.com)  
Mob: 07980 541 893 / 07584 391 303

**About Surgical Innovations Group plc**

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Repposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

📍 Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ, UK.

in @SurgicalInnovationsLtd

🐦 @Surginno

📺 @SurgicalInnovations

🌐 www.surginno.com



#### **Further information**

Further details of the Group's businesses and products are available on the following websites:

[www.sigroupplc.com](http://www.sigroupplc.com)

[www.surginno.com](http://www.surginno.com)

[www.elementalhealthcare.co.uk](http://www.elementalhealthcare.co.uk)

To receive regular updates by email, please contact [si@walbrookpr.com](mailto:si@walbrookpr.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTFFVIFFLDLIE